• 1
    Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 96273.
  • 2
    Tokita H, Okamoto H, Iizuka H, et al. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol 1996; 77: 293301.
  • 3
    Tokita H, Okamoto H, Luengrojanakul P, et al. Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 1995; 76: 232935.
  • 4
    Tokita H, Okamoto H, Tsuda F, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci USA 1994; 91: 110226.
  • 5
    Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 160710.
  • 6
    World Health Organization. Hepatitis C. WHO fact sheet 164. Available at (accessed 21 January 2009).
  • 7
    Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3 (Suppl. 2): S97101.
  • 8
    Ohno T, Mizokami M, Tibbs CJ, et al. New genotype of hepatitis C virus in South Africa. J Med Virol 1994; 42: 40913.
  • 9
    Smuts HE, Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995; 33: 167981.
  • 10
    Zhang YY, Lok AS, Chan DT, Widell A. Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. J Clin Microbiol 1995; 33: 29314.
  • 11
    Prescott LE, Simmonds P, Lai CL, et al. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. J Med Virol 1996; 50: 16875.
  • 12
    Wong DA, Tong LK, Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol 1998; 14: 4216.
  • 13
    Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 125965.
  • 14
    Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007. Available at (accessed 10 January 2009).
  • 15
    Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 137183.
  • 16
    Antaki N, Haddad M, Kebbewar K, et al. The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province. Epidemiol Infect 2008; 17: 16.
  • 17
    Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotype/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Med J 2003; 24: S8791.
  • 18
    Al-Kubaisy WA, Niazi AD, Kubba K. History of miscarriage as a risk factor for hepatitis C virus infection in pregnant Iraqi women. East Mediterr Health J 2002; 8: 23944.
  • 19
    Keyvani H, Alizadeh AHM, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res 2007; 37: 1013.
  • 20
    Bdour S. Hepatitis C virus infection in Jordanian hemodialysis units: serological diagnosis and genotyping. J Med Microbiol 2002; 51: 7004.
  • 21
    Sharara AI, Ramia S, Ramlawi F, et al. Genotypes of hepatitis C virus (HCV) among Lebanese patients: comparison of data with that from other middle Eastern countries. Epidemiol Infect 2007; 135: 42732.
  • 22
    Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity and response to interferon therapy. Ann Intern Med 1996; 125: 6349.
  • 23
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States. 1998 through 1994. N Engl J Med 1999; 341: 55662.
  • 24
    Elkashab M, Lee SS, Eiloart S, Marotta P, for the Canadian PEGAYS Study Group. Characteristics and outcome of treatment with peginterferon alfa-2a (PEGASYS) plus ribavirin (RBV) in patients with HCV genotype 4, 5, or 6 infection: analysis of the Canadian Pegasys Expanded Access Program (EAP). Can J Gastrol 2007; 21: 80A.
  • 25
    SistemaSistema Nacional de Vigilancia Epidemiológica (Si.Na.VE) de la Dir de Epidemiología del Ministerio de Salud y Ambiente de la Nación (MA).
  • 26
    World Health Organization. Hepatitis C – global prevalence (update). Wkly Epidemiol Rec 2000; 75: 1728.
  • 27
    Valdespinto JL, Olaiz G, Conde C, et al. Reto de Hepatitis C. Resumen de cifras para tomadores de decisiones. Instituto Nacional de Salud Pública. Mexico: Centro de Información para Decisiones en salud., 2005.
  • 28
    Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005; 12: 40513.
  • 29
    Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 14862.
  • 30
    Katsoulidou A, Sypsa V, Tassopoulos NC, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 1927.
  • 31
    Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001; 20: 417.
  • 32
    Cicciarello S, Borgia G, Crowell J, et al. Prevalence of hepatitis C virus genotypes in southern Italy. Eur J Epidemiol 1997; 13: 4954.
  • 33
    Gérard C, Delwaide J, Vaira D, et al. Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. J Med Virol 2005; 76: 50310.
  • 34
    Ross RS, Viazov S, Renzing-Köhler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000; 60: 1225.
  • 35
    Abacioglu YH, Davidson F, Tuncer S, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2: 297301.
  • 36
    Sánchez-Quijano A, Abad MA, Torronteras R, et al. Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997; 27: 259.
  • 37
    Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002; 68: 3526.
  • 38
    De Vries MJ, Te Rijdt B, Van Nieuwkerk CM. Genotype distribution amongst hepatitis C patients in The Netherlands. Neth J Med 2006; 64: 10913.
  • 39
    Tucker TJ, Voigt M, Bird A, et al. Hepatitis C virus infection rate in volunteer blood donors from the Western Cape comparison of screening tests and PCR. S Afr Med J 1997; 87: 6035.
  • 40
    Henquell C, Cartau C., Abergel A., et al. High prevalence of hepatitis C virus type 5 in Central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004; 42: 30305.
  • 41
    Verbeeck J, Maes P, Lemey P, et al. Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 2006; 80: 42206.
  • 42
    Jover R, Pérez-Serra J, De Vera F, et al. Infection by genotype 5a of HCV in a district of southeast Spain. Am J Gastroenterol 2001; 96: 30423.
    Direct Link:
  • 43
    Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76: 32732.
  • 44
    Zhao W., Xu D.P., Xue R., et al. Uneven geographic distribution of HCV genotypes across China. Hepatol Int 2009; 3: 77.
  • 45
    Tan Y, Wei QH, Chen LJ, et al. Molecular epidemiology of HCV monoinfection and HIV/HCV coinfection in injection drug users in Liuzhou, Southern China. PLoS One 2008; 3: e3608.
  • 46
    Peng JS, Wang X, Liu MQ, et al. Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res 2008; 135: 1916.
  • 47
    Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, et al. Various subtypes of hepatitis C virus genotype 6 found in central Thailand. Hepatol Int 2009; 3: 76.
  • 48
    Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005; 9: 41126.
  • 49
    Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C genotypes and viral concentrations in participants of general population survey in the United States. Gastroenterology 2006; 131: 47884.
  • 50
    Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 273743.
    Direct Link:
  • 51
    Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887912.
  • 52
    Rao MR, Naficy AB, Darwish MA, et al. Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt. BMC Infect Dis 2002; 2: 29.
  • 53
    El Katsha S, Labeeb S, Watts S, Younis A. Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. East Mediterr Health J 2006; 12: 75867.
  • 54
    Inhorn MC. Urban Egyptian women in the informal health care sector. In: LobbanRA, ed. Middle Eastern women and the invisible economy. Gainesville, FL: University Press of Florida, 1998.
  • 55
    National Population Council, Egypt & Macro International Inc. Egypt demographic and health survey, 1995. Chapter 13. Calverton, MD: National Population Council, Egypt & Macro International Inc., 1996.
  • 56
    Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 1027.
  • 57
    Talaat M, El-Oun S, Kandeel A, et al. Overview of injection practices in two governorates in Egypt. Trop Med Int Health 2003; 8: 23441.
  • 58
    Lohiniva AL, Talaat M, Bodenschatz C, et al. Therapeutic injections in the context of Egyptian culture. Promot Educ 2005; 12: 138.
  • 59
    Talaat M, Kandeel A, El-Shoubary W, et al. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003; 31: 46974.
  • 60
    Bassily S, Hyams K, Fouad R, Samaan M, Hibbs R. A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse. Am J Trop Med Hyg 1995; 52: 5035.
  • 61
    Magder LS, Fix AD, Mikhail NN, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005; 34: 1605.
  • 62
    Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004; 78: 122528.
  • 63
    Mudawi HM, Smith HM, Fletcher IA, Fedail SS. Prevalence and common genotypes of HCV infection in Sudanese patients with hepatosplenic schistosomiasis. J Med Virol 2007; 79: 13224.
  • 64
    Xu L-Z, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994; 75: 23938.
  • 65
    Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 2003; 84: 233341.
  • 66
    Simmonds P. Genetic diversity and evolution of hepatitis C virus – 15years on. J Gen Virol 2004; 85: 317388.
  • 67
    Muasya T, Lore W, Yano K, et al. Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East Afr Med J 2008; 85: 31825.
  • 68
    Njouom R, Nerrienet E, Dubois M, et al. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol 2007; 7: 3617.
  • 69
    Nicot F, Legrand-Abravanel F, Sandres-Saune K, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 2005; 86: 10714.
  • 70
    Delwaide J, Reenaers C, Gerard C, et al. HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin. Eur J Gastroenterol Hepatol 2006; 18: 70712.
  • 71
    Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and liver fibrosis. Gastroenterology 2008; 134: 41623.
  • 72
    Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 4518.
  • 73
    Diamantis I, Vafiadis I, Voskaridou E, et al. Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy. Eur J Gastroenterol Hepatol 1998; 10: 759.
  • 74
    Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factor and genotype distribution of HCV infection in the general population: a community-based survey in Southern Italy. Hepatology 1997; 26: 100611.
  • 75
    Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 43543.
  • 76
    Roulot D, Bourcier V, , Observational VHC4 Study Group. et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 14: 4607.
  • 77
    Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 16629.
  • 78
    Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004; 38: 6871.
  • 79
    Legrand-Abravanel F, Sandres-Sauné K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004; 189: 1397400.
  • 80
    Bonny C, Fontaine H, Poynard T, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther 2006; 24: 593600.
  • 81
    Delwaide J, Gerard C, Reenaers C, et al. Hepatitis C virus genotype 5 in Southern Belgium: epidemiological characteristics and response to therapy. Digest Dis Sci 2005; 50: 234851.
  • 82
    Bernier L, Willems B, Delage G, Murphy DG. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Med Microbiol 1996; 34: 28158.
  • 83
    Levi JE, Takaoka DT, Garrini RH, et al. Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients. J Med Microbiol 2002; 40: 26457.
  • 84
    Abergel A, Ughetto S, Dubost S, et al. The epidemiology and virology of hepatitis C virus genotype 5 in central France. Aliment Pharmacol Ther 2007; 26: 143746.
  • 85
    Seeff L. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S3546.
  • 86
    Kamal SM, Rasenack JW, Bianchi L, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121: 64656.
  • 87
    Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus specific T cell response kinetics. Hepatology 2004; 39: 172131.
  • 88
    Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006; 43: 7719.
  • 89
    Kamal SM, Graham CS, He Q, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4_ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 114050.
  • 90
    Esmat G, Metwally M, Zalata KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007; 46: 6207.
  • 91
    Soriano V, Mocroft A, EuroSIDA Study Group. et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198: 133744.
  • 92
    FreedmanLS, EdwardsBK, RiesLAG, YoungJL, eds. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. NIH Pub. No. 06-5873. Bethesda, MD: National Cancer Institute, 2006.
  • 93
    National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt. Available at (accessed 3 January 2009)
  • 94
    Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88 (Part 5): 152631.
  • 95
    Ezzat S, Abdel-Hamid M, Eissa SA, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005; 208: 32939.
  • 96
    Nieuwoudt M, Arazi A, Neumann A, Van der Merwe SW. Viral kinetics of HCV genotype 5 in South Africa patients treated with pegylated-interferon-alpha and ribavirin. Hepatology 2007; 46: 367A.
  • 97
    Seto WK, Lai CL, Fung J, et al. Interim analysis of the natural history of chronic hepatitis C genotype 1 and 6. Hepatology 2008; 48 (Suppl. 1): 1102A.
  • 98
    Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 6328.
  • 99
    Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 92331.
  • 100
    Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77: 669.
  • 101
    Soriano V, Núñez M, Sánchez-Conde M, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antiviral Ther 2005; 10: 16770.
  • 102
    Martín-Carbonero L, Puoti M, García-Samaniego J, et al. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. J Viral Hepat 2008; 15: 7105.
  • 103
    Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000; 132: 8456.
  • 104
    Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 1724.
  • 105
    Esmat GH, Abouzied A, Abdel-Hamid M, et al. Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. Hepatology 2003; 38 (Suppl.): 314A5A (abstract).
  • 106
    Shobokshi A, Serebour PE, Skakni L, et al. Combination therapy of peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003; 38 (Suppl.): 636A (abstract).
  • 107
    Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 17337.
    Direct Link:
  • 108
    Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004; 140: 723.
  • 109
    Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004; 24: 56874.
  • 110
    Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004; 20: 9318.
  • 111
    Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002; 35: 825.
  • 112
    Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 85866.
  • 113
    El-Zayadi AR, Attia M, Barakat EM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-a2b/ribavirin or induction-dose interferon-a2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005; 100: 244752.
  • 114
    Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12: 56928.
  • 115
    Kamal S, Kamary S, Shardell M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 173240.
  • 116
    Jessner W, Gschwantler M, Formann E, et al. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection. Antivir Ther 2008; 13: 5819.
  • 117
    Al Ashgar H, Helmy A, Khan MQ, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009; 29: 414.
  • 118
    Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L, et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a Spanish center. J Chemother 2007; 19: 4237.
  • 119
    Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009; 136: 85662.
  • 120
    Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 2009; 29 (Suppl. 1): 3948 (review).
  • 121
    Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 95460.
  • 122
    D'Heygere F, George C, Nevens F, et al. Patients infected with HCV-5 present the same response rate as patients infected with HCV-1: results from the Belgian randomized trial for naïve and relapsers (BERNAR-1) [abstract]. J Hepatol 2005; 42: 203A.
  • 123
    Antaki N, Hermes A, Hadad M, et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008; 15: 3836.
  • 124
    Hui CK, Yuen MF, Sablon E, et al. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 10714.
  • 125
    Fung J, Lai CL, Hung I, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 80812.
  • 126
    Nguyen MH, Trinh HN, Garcia R, et al. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 11315.
    Direct Link:
  • 127
    Li F, Ng TL, Tai LF, et al. High response rate of combination therapy of pegylated interferon and ribavirin in treating chronic hepatitis C with genotype 6A in Hong Kong Chinese. Hepatol Int 2009; 3: 164.
  • 128
    PThi TT, Ho TD. Pegylated interferon alfa-2a plus ribavirin in chronic hepatitis C patient with genotype 6. Hepatol Int 2009; 3: 49.
  • 129
    Antaki N, Marcellin P. What is the safe duration of therapy for patients infected with HCV genotype 6? Nat Clin Pract Gastroenterol Hepatol 2009; 6: 789.